Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Vir Biotechnology: The Low-Down On The Readouts Ahead [Seeking Alpha]
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.